People love talking success at Meeting on the Mesa.
(No wonder Aava™ comes up so naturally in conversation.)

Phoenix, AZ  |  October 5-7, 2026

Business gets done at Meeting on the Mesa because everyone’s seeking collaborations to take on the CGT world’s toughest challenges. For our part, we’ll be ready to listen and understand what’s required to ensure your next step is your best one yet. And then together, we can find out if our Aava™ platform — and the ways it delivers on our promise of worry-free AAV manufacturing — is an ideal fit for your program:

  • Better Foresight: Leverage 1,500+ batches’ worth of data to signal early predictability of your construct
  • Superior Speed: Scale faster from research to clinical to commercial while reducing PD and validation timelines
  • Deeper Data: Simplify and de-risk your registration process through access to our CMC package and data management

Now that you know a little about us, let’s meet and talk about you.

Two solid options.
One best-fit choice.

Aava wordmark white

 

The version of Aava™ that’s right for you depends on your drivers: If speed and stability are top-of-mind, then Mendi might be the way to go; if scale and efficiency are the priority, Iturri may be the better fit. Either way, Aava™ can be adapted to fit your specific needs to help you achieve your manufacturing goals. Start by learning more here.

Fresh research on AAV manufacturing

Stop by Poster Hall 12 throughout the week for a quintet of research updates from the scientific and technology leads at Viralgen who are helping shape the future of AAV-based gene therapy manufacturing.

Streamlining Advanced Therapy Medicinal Product Manufacturing: A Platform Approach for Accelerating Gene Therapy Commercialization at Viralgen
Presented by Cesar Trigueros
May 15, 5:30-7pm CT
Poster Hall I2
Poster # AMA988

Benefits of High-Throughput Sequencing-Based Methods for In-Depth Characterization of Recombinant AAV Products
Presented by Sonia Stinus
May 14, 5:30-7pm CT
Poster Hall I2
Poster # AMA905

Enhancing the Upstream Performance of Adeno-Associated Virus (AAV) Vector Manufacturing via Multivariate Data Analysis
Presented by Ainara Apezteguia
May 15, 5:30-7pm CT
Poster Hall I2
Poster # AMA1624

Leveraging Historical Data and Percentile based Modeling for Improved AAV Production Scaling
Presented by Itsasne Arangoa
May 15, 5:30-7pm CT
Poster Hall I2
Poster # AMA1546

Integrating Raman Spectroscopy and Genome-Scale Modeling to Enhance AAV Upstream Manufacturing
Presented by Itsasne Arangoa
May 13, 6-7:30pm CT
Poster Hall I2
Poster # AMA1539

Let’s Connect

Bayer fully supports coordinated vulnerability disclosure and encourages security researchers who choose to engage in these actions to do so in a responsible manner.

Coordinated Vulnerability Disclosure Statement

Phoenix is just the start: Learn more here
All the Pieces Fit – and All the Pieces Matter: An Update on Holistic CSR with Viralgen CEO Jimmy Vanhove
All the Pieces Fit – and All the Pieces Matter: An Update on Holistic CSR with Viralgen CEO Jimmy Vanhove
A 2025 analysis published in the International Journal of Financial Studies drew a clear, direct correlation between corporate social responsibility (CSR) and performance: Put simply, companies that win in CSR outperform their peers. It’s a business...
READ MORE
July 27, 2026
Supporting Innovation Through AAV Manufacturing: A Visit from Donostia Mayor
Supporting Innovation Through AAV Manufacturing: A Visit from Donostia Mayor
The visit of Donostia / San Sebastián Mayor Jon Insausti to Viralgen was an opportunity to open our doors and share, once again, what we do and why it matters: supporting the development and manufacturing of AAV-based gene therapies that aim to...
READ MORE
July 10, 2026
Viralgen @ ASGCT: What We Saw, What To Keep An Eye On
Viralgen @ ASGCT: What We Saw, What To Keep An Eye On
ASGCT in Boston was, as always, packed with people, posters, innovations, and insights. It’s an exciting time, and a great opportunity to reconnect with peers and discover great science. Now that the Viralgen team has had a chance to share notes and...
READ MORE
June 01, 2026